Follow-On Biologics Would Increase Savings By 30 Percent With Coding Tweaks, CBO Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Even without reimbursement changes, CBO estimates higher Medicare/Medicaid savings than in previous scoring of Senate bill.
You may also be interested in...
Senate Follow-On Biologics Bill Still Stuck In Evergreen Forest
Despite moving a bill out of committee last session, the Senate is still wrangling over the issue of whether modifications of existing products should get full exclusivity.
Senate Follow-On Biologics Bill Still Stuck In Evergreen Forest
Despite moving a bill out of committee last session, the Senate is still wrangling over the issue of whether modifications of existing products should get full exclusivity.
BIO Study On Follow-On Biologics Focuses On Trade-Off Between Savings And R&D
Study extrapolates from CBO’s scoring of last year’s Senate bill to argue that “shorter exclusivity could lead to the worst of both worlds – fewer new biologics … and little savings.”